Allergan (AbbVie) Deal History & Licensing Activity
Allergan (AbbVie) is a large pharma headquartered in US. Over the past three years, Allergan (AbbVie) has been involved in 10 licensing and acquisition transactions, with a primary focus on Small Molecules (10 deals). The company currently has 50 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
4
Active Trials
50
Top Modality
Small Molecules
Focus Area
Hematological Malignancies
Allergan (AbbVie) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Allergan (AbbVie) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| KST-6051 | AbbVie | Small Molecules | Unknown | acquisition | Apr 15, 2026 |
| HSK55718 and HSK51155 | AbbVie | Small Molecules | Preclinical | license | Apr 14, 2026 |
| reproxalap | Aldeyra Therapeutics | Small Molecules | Phase 3 | option |
Allergan (AbbVie) Pipeline Focus
Therapeutic areas and modalities where Allergan (AbbVie) is most active based on deal history and clinical trial data.
Therapeutic Areas
Allergan (AbbVie) Strategic Signals
Key indicators of Allergan (AbbVie)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Allergan (AbbVie) Clinical Pipeline
Allergan (AbbVie) has 50 active clinical trials across 5 development phases.
3
Phase 4
8
Unknown
21
Phase 1
15
Phase 2
3
Phase 3
See How Your Asset Matches Allergan (AbbVie)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Allergan (AbbVie) Licensing & Deal Activity
Allergan (AbbVie) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, Allergan (AbbVie) ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Allergan (AbbVie) include Hematological Malignancies (9 deals and trials), Ophthalmology (8 deals and trials), Solid Tumors (6 deals and trials), and Autoimmune (5 deals and trials). In terms of modality, Allergan (AbbVie) has shown particular interest in small molecules, small molecules, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Allergan (AbbVie) and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Allergan (AbbVie)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.